ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) reached a new 52-week low during trading on Friday . The company traded as low as $2.96 and last traded at $3.02, with a volume of 565652 shares trading hands. The stock had previously closed at $3.04.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on IBRX shares. D. Boral Capital restated a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Thursday, November 21st. Piper Sandler cut their price objective on ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday, August 19th. Finally, EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd.
Read Our Latest Analysis on ImmunityBio
ImmunityBio Price Performance
The stock has a market capitalization of $2.00 billion, a P/E ratio of -3.12 and a beta of 0.86. The stock's fifty day moving average is $4.56 and its two-hundred day moving average is $4.87.
Hedge Funds Weigh In On ImmunityBio
Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its stake in ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company's stock valued at $3,928,000 after buying an additional 170,742 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at approximately $118,000. Rhumbline Advisers grew its position in ImmunityBio by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 211,677 shares of the company's stock worth $1,338,000 after purchasing an additional 24,802 shares in the last quarter. Wealth Effects LLC raised its stake in ImmunityBio by 33.6% during the 2nd quarter. Wealth Effects LLC now owns 87,500 shares of the company's stock valued at $553,000 after purchasing an additional 22,000 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of ImmunityBio by 16.0% in the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock valued at $126,000 after purchasing an additional 2,746 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
